Immune Tolerance Induction: Is It Cost Effective? We Know Too Little

ABSTRACT

The development of an inhibitor in a hemophiliac is a serious clinical problem. Many inhibitors have high titers, and thus one cannot guarantee hemostasis. The prevalence of this transfusion-transmitted disease reaches as high as 35%, even with newer products. The costs of product use for inhibitor patients are significantly higher than for those without an inhibitor. For more than 20 years, using the concept of antigen overload, several regimens have existed for the induction of immune tolerance to eradicate these inhibitors. Registries exist reviewing the results of these regimens in the United States and internationally. Although much has been garnered about predictors of outcomes, we have much to learn about who the ideal candidates are, what optimal regimens are, and when to stop, as well as how to maintain a success. The costs of managing an inhibitor patient with and without human immunodeficiency virus (HIV) have caused managed care programs to seriously challenge the use of these regimens. Data are needed to provide the cost benefit of immune tolerance.

KEYWORD

Inhibitors - tolerance - costs - factor VIII - registries

REFERENCES

• 1 Lusher J M, Arkin S, Abildgaard C F, Schwartz R S, Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and the development of inhibitors.  N Engl J Med . 1993;  328 453-459
• 2 Bray G, Gomperts E D, Courter S. A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy and inhibitor risk in previously untreated patients with hemophilia A.  Blood . 1994;  83 2428-2435
• 3 Prescott R, Nakai H, Saenko E L. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.  Blood . 1997;  89 3663-3671
• 4 Brackman H H. Induced immunotolerance for factor VIII inhibitor patients.  Prog Clin Biol Res . 1984;  150 181-195
• 5 White II C G, Taylor R E, Blatt P M, Roberts H R. Treatment of a high titer antifactor-VIII antibody by continuous factor VIII administration: Report of a case.  Blood . 1983;  62 141-145
• 6 Van Leeuwen F E, Mauser-Bunschoten E P, Van Dijken J P. Disappearance of factor VIII:C antibodies in patients with hemophilia A upon frequent administration of factor VIII in intermediate or low dose.  Br J Haematol . 1986;  64 291-297
• 7 Aznar J A, Jorquera J I, Peiro A. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A.  Thromb Haemost . 1984;  151 217-221
• 8 Nilsson I M, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.  N Engl J Med . 1988;  318 947-950
• 9 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry: Report of the factor VIII and IX Subcommittee.  Thromb Haemost . 1994;  72 155-158
• 10 DiMichele D M, Kroner B L. Analysis of the North American Immune Tolerance Registry (NAITR) (1993-1997): Current practice implications.  Blood . 1997;  90(suppl 1) (Abstract) 156a
• 11 Bohn R L, Avorn J, Glynn R J. Prophylactic use of factor VIII: An economic evaluation.  Thromb Haemost . 1998;  79 932-937
• 12 Warrier I, Ewenstein B M, Koerper M. Factor IX inhibitors and anaphylaxis in hemophilia B.  Am J Pediatr Hematol Oncol . 1997;  19 23-27
• 13 Ewenstein B M, Takemoto C, Warrier I. Nephrotic syndrome as a complication of immune tolerance in hemophilia B.  Blood . 1997;  89 (Letter) 115-116
• 14 New Directions in the Treatment of Hemophilia with Inhibitors: Continued Professional Education for Physicians, Nurses & Pharmacists. Copenhagen, Denmark: Novo Nordisk Pharmaceuticals, Inc. 1998
• 15 Aledort L M, Miners A, Bohn R. Meeting report: Economic aspects of haemophilia care.  Haemophilia . 1999;  5 216-219
• 16 Lipton R A. The economics of factor VIII inhibitor treatment.  Semin Hematol . 1994;  37-38 (37-38)
• 17 Aledort L M, the Baxter Previously Untreated Patient Study Group. Immune tolerance in hemophiliacs: Can we afford it?.  <~>Is it worth it? Transfusion . 1999;  39 1034-1035
• 18 Leisner R J, Vora A J, Hann I M, Lilleymann J S. Use of central venous catheters in children with severe congenital coagulopathy.  Br J Haematol . 1995;  91 201-207
• 19 Ragni M V, Hord J D, Blatt J. Central venous catheter infection in haemophiliacs undergoing prophylaxis or immune tolerance with clotting factor concentrate.  Haemophilia . 1997;  3 90-95
• 20 Kreuz W, Ehrenforth S, Funk M. Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up.  Haemophilia . 1995;  1 24-32
• 21 Colowick A B, Bohn R, Avorn J L, Ewenstein B M. Immune tolerance induction for hemophilia A patients with inhibitors: A cost-effectiveness analysis.  Blood. 1998;  92(suppl 1) (Abstract) 553a